{"protocolSection": {"identificationModule": {"nctId": "NCT00207740", "orgStudyIdInfo": {"id": "CR005281"}, "secondaryIdInfos": [{"id": "C0524T03", "type": "OTHER", "domain": "Centocor"}], "organization": {"fullName": "Centocor, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma", "officialTitle": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2012-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-08"}, "primaryCompletionDateStruct": {"date": "2007-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-13", "studyFirstSubmitQcDate": "2005-09-13", "studyFirstPostDateStruct": {"date": "2005-09-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-21", "resultsFirstSubmitQcDate": "2012-05-01", "resultsFirstPostDateStruct": {"date": "2012-06-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-08-14", "lastUpdatePostDateStruct": {"date": "2012-08-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Centocor, Inc.", "class": "INDUSTRY"}, "collaborators": [{"name": "Centocor BV", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.", "detailedDescription": "This is a multicenter, randomized (the study medication is assigned by chance), double-blind (neither physician nor patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical study), parallel-group (each group of patients will be treated at the same time), dose-ranging study to evaluate the efficacy and safety of CNTO 148. The study will consists of run-in phase (2 weeks), treatment period (52 weeks) and follow up period (24 weeks). The patients inhaled corticosteroids (ICS) medication will be standardized in the run-in phase and the treatment period contains first 24 weeks of treatment, the patients are required to remain on stable doses of concomitant corticosteroids (CS) medication (steroid stable phase). The steroid stable phase is followed by a 28-week steroid taper phase, during which a reduction of concomitant CS medication will be attempted. After completion of the study treatment, patients are to be followed for an additional 24 weeks. Patients will receive subcutaneous injections of 75, 150, or 300 mg of CNTO 148 or placebo every 4 weeks for 52 weeks followed 50,100, or 200 mg every 4 weeks through week 52. The safety of the patient will be monitored throughout the study."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Severe Persistent Asthma", "Subcutaneous injections", "Immunology disorder", "Breathlesness"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 309, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "CNTO 148 (golimumab)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: CNTO148"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "CNTO148", "description": "Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms", "armGroupLabels": ["CNTO 148 (golimumab)"]}, {"type": "DRUG", "name": "Placebo", "description": "Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Prebronchodilator Clinic-Measured, Percent-Predicted Forced Expiratory Volume in 1 Second", "description": "The endpoint is change from baseline in prebronchodilator clinic-measured percent predicted Percent-Predicted Forced Expiratory Volume in 1 Second (FEV1) with Last Observation Carried Forward (LOCF) at 6 months. The baseline visit starts at the end of 2 weeks run in phase.", "timeFrame": "Baseline and Week 24"}, {"measure": "Number of Severe Asthma Exacerbations Per Patient From Baseline Through 6 Months", "description": "The endpoint is the average number of severe asthma exacerbations per patient from baseline through 6 months.", "timeFrame": "Baseline to Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Asthma Quality of Life Questionnaire Score at 6 Months; Randomized Patients", "description": "The endpoint is the change from baseline in the overall Asthma Quality of Life Questionnaire (AQLQ) score at 6 months. The AQLQ is a validated and self-administered questionnaire to evaluate symptoms and Quality of Life (QOL) in subjects with asthma and it has 32 questions in 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to score the importance of each of the positively identified problems on a 7-point scale (7 = not impaired at all - 1 = severely impaired).", "timeFrame": "Baseline to Week 24"}, {"measure": "Change From Baseline in Rescue Medication Use at 6 Months; Randomized Patients", "description": "The endpoint is change from baseline in rescue medication use at Wk 24 where the rescue medication use was based on the average over 7 days prior to visit.", "timeFrame": "Baseline to Week 24"}, {"measure": "Number of Severe Asthma Exacerbations Per Patient From Week 24 Through Week 52; Randomized Patients Who Did Not Discontinue Study Participation Prior to Week 24", "description": "The endpoint is the average number of severe asthma exacerbations per patient from Week (Wk) 24 through Wk 52 for the patients who did not discontinue study participation prior to Wk 24", "timeFrame": "Week 24 to Week 52"}, {"measure": "Change From Baseline in Oral Corticosteroids Dose at Week 52; Randomized Patients Who Received Oral Corticosteroids at Baseline", "description": "The endpoint is the change from baseline at Week (Wk) 52 in oral corticosteroids (OCS) dose for the randomized patients who received OCS at baseline.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Domiciliary Morning Peak Expiratory Flow Rate (PEFR) at 6 Months; Randomized Subjects", "description": "The endpoint is the change from baseline in domiciliary morning PEFR at Week 24. PEFR- Peak Expiratory Flow Rate (PEFR): A measure of the speed of exhalation. The data were collected in the eDiary which was issued to each participant at screening. PEFR was collected morning and evening each day of the study.", "timeFrame": "Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Physician diagnosis of asthma for greater than or equal to 3 years and a diagnosis of severe persistent asthma forgreater than or equal to 1 year prior to screening\n* Continuous treatment with high dose Inhaled corticosteroids (ICS) and long acting beta-agonist for at least 3 months prior to screening\n* Have evidence of at least 1 of the following in the 5 years prior to screening or during screening, reversible airway obstruction greater than or equal to 12 percentage change in forced expiratory volume in 1 second (FEV1) postbronchodilator; Diurnal variation in peak expiratory flow rate (PEFR) greater than or equal to 30 percentage change) and airway hyperresponsiveness\n* Estimated frequency of symptoms on more than one-third of days for at least 3 months prior to screening (eg, wheezing, breathlessness, chest tightness, cough, nocturnal awakening) despite treatment with high dose ICS and long-acting \u03b22-agonist (LABA), with or without continuous oral corticosteroids\n* Score of greater than or equal to 2 points on the asthma control questionnaire at screening.\n\nExclusion Criteria:\n\n* Diagnosis of chronic obstructive pulmoanry disease (COPD), cystic fibrosis, or other significant respiratory disorder\n* Worsening of asthma symptoms that required treatment with an addition or increase in oral corticosteroids dose (steroid burst) in the 4-week period prior to the screening visit\n* Life-threatening asthma attack requiring cardiopulmonary support (eg, intubation) in the 6-month period prior to screening\n* Have ever used alkylating agents (eg, chlorambucil or cyclophosphamide)\n* Concomitant diagnosis or any history of congestive heart failure (CHF), including medically controlled CHF.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Centocor, Inc. Clinical Trial", "affiliation": "Centocor, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"city": "Hartford", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.76371, "lon": -72.68509}}, {"city": "New Haven", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"city": "Normal", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"city": "River Forest", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"city": "Iowa City", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"city": "Boston", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"city": "Minneapolis", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"city": "Saint Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "Cortland", "state": "New York", "country": "United States", "geoPoint": {"lat": 42.60118, "lon": -76.18048}}, {"city": "Elmira", "state": "New York", "country": "United States", "geoPoint": {"lat": 42.0898, "lon": -76.80773}}, {"city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Cleveland", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"city": "Lake Oswego", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"city": "Bellingham", "state": "Washington", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"city": "Gent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"city": "Russel", "country": "Bulgaria"}, {"city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Ostrava", "country": "Czech Republic", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"city": "Poruba", "country": "Czech Republic"}, {"city": "Usti Nad Labem", "country": "Czech Republic", "geoPoint": {"lat": 50.6607, "lon": 14.03227}}, {"city": "Montpellier Cedex 9", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"city": "Pessac", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"city": "Tarbes", "country": "France", "geoPoint": {"lat": 43.23333, "lon": 0.08333}}, {"city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Gro\u00dfhansdorf", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"city": "Nyiregyhaza", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"city": "Szekesfehervar", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"city": "Szombathely", "country": "Hungary", "geoPoint": {"lat": 47.23088, "lon": 16.62155}}, {"city": "T\u00f6r\u00f6kb\u00e1lint", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"city": "Leiden", "country": "Netherlands", "geoPoint": {"lat": 52.15833, "lon": 4.49306}}, {"city": "Bienkowka", "country": "Poland", "geoPoint": {"lat": 49.776, "lon": 19.77179}}, {"city": "Katowice", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"city": "Torun", "country": "Poland", "geoPoint": {"lat": 53.01375, "lon": 18.59814}}, {"city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Linkoeping", "country": "Sweden"}, {"city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"city": "Glasgow", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"city": "Southampton", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "19136369", "type": "DERIVED", "citation": "Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "A total of 309 patients were randomized into 4 parallel treatment groups at 53 sites (134 patients at 27 sites in the US and 175 patients at 26 sites in Europe). The first patient was consented on 31 Aug 2004, and the last patient completed the study on 17 Jul 2007.", "groups": [{"id": "FG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "FG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab (CNTO148) 75 mg SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "FG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "FG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}, {"groupId": "FG001", "numSubjects": "77"}, {"groupId": "FG002", "numSubjects": "76"}, {"groupId": "FG003", "numSubjects": "78"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Indicates number of patients who received subcutaneous study medication through Week 52", "numSubjects": "49"}, {"groupId": "FG001", "comment": "Indicates number of patients who received subcutaneous study medication through Week 52", "numSubjects": "36"}, {"groupId": "FG002", "comment": "Indicates number of patients who received subcutaneous study medication through Week 52", "numSubjects": "36"}, {"groupId": "FG003", "comment": "Indicates number of patients who received subcutaneous study medication through Week 52", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "41"}, {"groupId": "FG002", "numSubjects": "40"}, {"groupId": "FG003", "numSubjects": "43"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Sponsor Directive", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "21"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "BG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab (CNTO148) 75 mg SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "BG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "BG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "76"}, {"groupId": "BG003", "value": "78"}, {"groupId": "BG004", "value": "309"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.4", "spread": "12.03"}, {"groupId": "BG001", "value": "49.4", "spread": "11.26"}, {"groupId": "BG002", "value": "49.1", "spread": "12.85"}, {"groupId": "BG003", "value": "52.7", "spread": "12.26"}, {"groupId": "BG004", "value": "50.1", "spread": "12.14"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "46"}, {"groupId": "BG004", "value": "173"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "32"}, {"groupId": "BG004", "value": "136"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Prebronchodilator Clinic-Measured, Percent-Predicted Forced Expiratory Volume in 1 Second", "description": "The endpoint is change from baseline in prebronchodilator clinic-measured percent predicted Percent-Predicted Forced Expiratory Volume in 1 Second (FEV1) with Last Observation Carried Forward (LOCF) at 6 months. The baseline visit starts at the end of 2 weeks run in phase.", "populationDescription": "The analysis of this endpoint uses intent-to-treat population. Missing data were imputed using Last Observation Carried Forward (LOCF).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent predicted", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab (CNTO148) 75 milligram (mg) SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.44", "lowerLimit": "-0.574", "upperLimit": "5.461"}, {"groupId": "OG001", "value": "0.48", "lowerLimit": "-2.563", "upperLimit": "3.519"}, {"groupId": "OG002", "value": "3.22", "lowerLimit": "0.149", "upperLimit": "6.295"}, {"groupId": "OG003", "value": "2.59", "lowerLimit": "-0.441", "upperLimit": "5.620"}, {"groupId": "OG004", "value": "2.91", "lowerLimit": "0.696", "upperLimit": "5.116"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the endpoint for placebo is the same as that for combined 100 mg and 200 mg golimumab. Assuming a standard deviation of 23%, there is 86% power to detect a 10% difference at a 0.05 significance level.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.802", "pValueComment": "When interpreting this p-value along with the other co-primary endpoint, Hochberg procedure was used.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "This is a secondary analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.945", "pValueComment": "The nominal p-value is for descriptive purpose only.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "This is a secondary analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.717", "pValueComment": "The nominal p-value is for descriptive purpose only.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "This is a secondary analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.357", "pValueComment": "The nominal p-value is for descriptive purpose only.", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire Score at 6 Months; Randomized Patients", "description": "The endpoint is the change from baseline in the overall Asthma Quality of Life Questionnaire (AQLQ) score at 6 months. The AQLQ is a validated and self-administered questionnaire to evaluate symptoms and Quality of Life (QOL) in subjects with asthma and it has 32 questions in 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to score the importance of each of the positively identified problems on a 7-point scale (7 = not impaired at all - 1 = severely impaired).", "populationDescription": "The analysis of this endpoint uses intent-to-treat population. Missing data were imputed using last observation carried forward.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Points on scale", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab (CNTO148) 75 milligram (mg) SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.42", "lowerLimit": "0.00", "upperLimit": "1.13"}, {"groupId": "OG001", "value": "0.53", "lowerLimit": "0.00", "upperLimit": "1.13"}, {"groupId": "OG002", "value": "0.86", "lowerLimit": "-0.02", "upperLimit": "1.47"}, {"groupId": "OG003", "value": "0.55", "lowerLimit": "0.00", "upperLimit": "1.00"}, {"groupId": "OG004", "value": "0.66", "lowerLimit": "0.00", "upperLimit": "1.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the endpoint for placebo is the same as that in the combined 100 mg and 200 mg golimumab.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.286", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.742", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.128", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.946", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "PRIMARY", "title": "Number of Severe Asthma Exacerbations Per Patient From Baseline Through 6 Months", "description": "The endpoint is the average number of severe asthma exacerbations per patient from baseline through 6 months.", "populationDescription": "The analysis of this endpoint uses intent-to-treat population. For the dropouts, the worst case in similar patients was used as the number of severe exacerbations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Events per patient through week (Wk) 24", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab 75 milligram (mg) SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "1.07", "lowerLimit": "0.0", "upperLimit": "1.0"}, {"groupId": "OG001", "value": "0.7", "spread": "1.18", "lowerLimit": "0.0", "upperLimit": "1.0"}, {"groupId": "OG002", "value": "0.4", "spread": "0.85", "lowerLimit": "0.0", "upperLimit": "0.5"}, {"groupId": "OG003", "value": "0.5", "spread": "1.08", "lowerLimit": "0.0", "upperLimit": "1.0"}, {"groupId": "OG004", "value": "0.5", "spread": "0.97", "lowerLimit": "0.0", "upperLimit": "1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the number of severe exacerbations per patient from baseline through week 24 for placebo is the same as that in the combined 100 mg and 200 mg golimumab. Assuming 1 severe exacerbation over 6 months per patient in the placebo group, there is 79% power to detect a 35% reduction in the combined 100 mg and 200 mg golimumab group at a 0.05 significance level.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.718", "pValueComment": "When interpreting this p-value along with the other co-primary endpoint, Hochberg procedure was used.", "statisticalMethod": "Cochran-Mantel-Haenszel"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "This is a secondary analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.779", "pValueComment": "The nominal p-value is for descriptive purpose only.", "statisticalMethod": "Cochran-Mantel-Haenszel"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "This is a secondary analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.649", "pValueComment": "The nominal p-value is for descriptive purpose only.", "statisticalMethod": "Cochran-Mantel-Haenszel"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "This is a secondary analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.256", "pValueComment": "The nominal p-value is for descriptive purpose only.", "statisticalMethod": "Cochran-Mantel-Haenszel"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Rescue Medication Use at 6 Months; Randomized Patients", "description": "The endpoint is change from baseline in rescue medication use at Wk 24 where the rescue medication use was based on the average over 7 days prior to visit.", "populationDescription": "The analysis of this endpoint uses intent-to-treat population. Missing data were imputed using last observation carried forward.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Puffs/day", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab 75 mg SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "lowerLimit": "-1.57", "upperLimit": "0.50"}, {"groupId": "OG001", "value": "-0.71", "lowerLimit": "-1.71", "upperLimit": "0.52"}, {"groupId": "OG002", "value": "-0.29", "lowerLimit": "-1.79", "upperLimit": "0.26"}, {"groupId": "OG003", "value": "-0.14", "lowerLimit": "-1.67", "upperLimit": "0.67"}, {"groupId": "OG004", "value": "-0.21", "lowerLimit": "-1.71", "upperLimit": "0.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the endpoint for placebo is the same as that in the combined 100 mg and 200 mg golimumab.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.894", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.572", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.731", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.856", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Number of Severe Asthma Exacerbations Per Patient From Week 24 Through Week 52; Randomized Patients Who Did Not Discontinue Study Participation Prior to Week 24", "description": "The endpoint is the average number of severe asthma exacerbations per patient from Week (Wk) 24 through Wk 52 for the patients who did not discontinue study participation prior to Wk 24", "populationDescription": "Analysis of this endpoint only includes patients (pts) who did not discontinue study participation prior to Wk 24. For the dropouts during the period between Wks 24- 52, worst case in similar pts was used as the number of severe exacerbations. Data from Wk 24-52 must be interpreted with caution as study agent was stopped at various study timepoints", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Events per patient from Wk 24 thru Wk 52", "timeFrame": "Week 24 to Week 52", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from Wk 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab 75 milligram (mg) SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "71"}, {"groupId": "OG003", "value": "74"}, {"groupId": "OG004", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "1.02", "lowerLimit": "0.0", "upperLimit": "1.0"}, {"groupId": "OG001", "value": "0.8", "spread": "1.23", "lowerLimit": "0.0", "upperLimit": "2.0"}, {"groupId": "OG002", "value": "0.9", "spread": "1.18", "lowerLimit": "0.0", "upperLimit": "2.0"}, {"groupId": "OG003", "value": "0.8", "spread": "1.01", "lowerLimit": "0.0", "upperLimit": "2.0"}, {"groupId": "OG004", "value": "0.9", "spread": "1.09", "lowerLimit": "0.0", "upperLimit": "2.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the endpoint for placebo is the same as that in the combined 100 mg and 200 mg golimumab.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.273", "statisticalMethod": "Cochran-Mantel-Haenszel"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.382", "statisticalMethod": "Cochran-Mantel-Haenszel"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.350", "statisticalMethod": "Cochran-Mantel-Haenszel"}, {"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.341", "statisticalMethod": "Cochran-Mantel-Haenszel"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Oral Corticosteroids Dose at Week 52; Randomized Patients Who Received Oral Corticosteroids at Baseline", "description": "The endpoint is the change from baseline at Week (Wk) 52 in oral corticosteroids (OCS) dose for the randomized patients who received OCS at baseline.", "populationDescription": "Analysis of this endpoint includes only pts who received OCS at baseline.Wk 52 OCS dose is the daily OCS dose in the last period, defined as between 2 consecutive visits, in which no change in total daily dose of OCS occurred, prior to Wk 52 visit.Data from Wk 24-52 must be interpreted with caution as study agent was stopped at various timepoints.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mg/day P. Eq.", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from Wk 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab 75 mg SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.000", "lowerLimit": "-10.000", "upperLimit": "0.000"}, {"groupId": "OG001", "value": "0.000", "lowerLimit": "-5.000", "upperLimit": "0.000"}, {"groupId": "OG002", "value": "-4.550", "lowerLimit": "-10.000", "upperLimit": "0.000"}, {"groupId": "OG003", "value": "-3.750", "lowerLimit": "-10.000", "upperLimit": "0.000"}, {"groupId": "OG004", "value": "-4.550", "lowerLimit": "-10.000", "upperLimit": "0.000"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the endpoint for placebo is the same as that in the combined 100 mg and 200 mg golimumab.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.986", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.820", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.858", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.021", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Domiciliary Morning Peak Expiratory Flow Rate (PEFR) at 6 Months; Randomized Subjects", "description": "The endpoint is the change from baseline in domiciliary morning PEFR at Week 24. PEFR- Peak Expiratory Flow Rate (PEFR): A measure of the speed of exhalation. The data were collected in the eDiary which was issued to each participant at screening. PEFR was collected morning and evening each day of the study.", "populationDescription": "The analysis of this endpoint uses intent-to-treat population. Missing data were imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 weeks (Wks) from week (Wk) 0 to Wk 52"}, {"id": "OG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab 75 mg SC injection at Wk 0 followed by 50 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 Wks to Wk 52"}, {"id": "OG004", "title": "Combined: Group III & IV", "description": "Combines Group III (golimumab 100 mg) and Group IV (golimumab 200 mg)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.730", "spread": "60.9136"}, {"groupId": "OG001", "value": "8.102", "spread": "58.0602"}, {"groupId": "OG002", "value": "3.488", "spread": "60.1336"}, {"groupId": "OG003", "value": "2.475", "spread": "59.7923"}, {"groupId": "OG004", "value": "2.975", "spread": "59.7668"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis was that the endpoint for placebo is the same as that in the combined 100 mg and 200 mg golimumab.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.833", "statisticalMethod": "ANOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.814", "statisticalMethod": "ANOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.897", "statisticalMethod": "ANOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.726", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Group I: Placebo", "description": "Placebo subcutaneous (SC) injections every 4 wks from Wk 0 to Wk 52", "seriousNumAffected": 16, "seriousNumAtRisk": 78, "otherNumAffected": 75, "otherNumAtRisk": 78}, {"id": "EG001", "title": "Group II: Golimumab 50 mg", "description": "Golimumab (CNTO148) 75 mg SC injection at Wk 0 followed by 50 mg SC injections every 4 wks to Wk 52", "seriousNumAffected": 24, "seriousNumAtRisk": 75, "otherNumAffected": 68, "otherNumAtRisk": 75}, {"id": "EG002", "title": "Group III: Golimumab 100 mg", "description": "Golimumab 150 mg SC injection at Wk 0 followed by 100 mg SC injections every 4 wks to Wk 52", "seriousNumAffected": 24, "seriousNumAtRisk": 78, "otherNumAffected": 75, "otherNumAtRisk": 78}, {"id": "EG003", "title": "Group IV: Golimumab 200 mg", "description": "Golimumab 300 mg SC injection at Wk 0 followed by 200 mg SC injections every 4 wks to Wk 52", "seriousNumAffected": 22, "seriousNumAtRisk": 78, "otherNumAffected": 75, "otherNumAtRisk": 78}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 78}]}, {"term": "Diffuse panbronchiolitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pneumonitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pleurisy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Respiratory distress", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Bursitis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Choriomeningitis lymphocytic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Escherichia bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Gastrointestinal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Herpes simplex", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Staphylococcal bacteraemia", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Gastric haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Lower gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Pneumatosis intestinalis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "B-cell lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Cervix carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Metastases to lung", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Metastases to lymph nodes", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Prostatic adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Renal cell carcinoma stage unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Hyperthermia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Pericarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Breast mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Prostatitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Serum sickness", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Procedural nausea", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Borderline personality disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 78}]}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 71, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 64, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 69, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 72, "numAtRisk": 78}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 78}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 78}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 78}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 78}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 78}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 78}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 78}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 78}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 78}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in \\<= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "Director Clinical Research", "organization": "Centocor Research & Development, Inc.", "phone": "1-800-457-6399"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Italy"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000529000", "term": "Golimumab"}], "ancestors": [{"id": "D000079424", "term": "Tumor Necrosis Factor Inhibitors"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M150496", "name": "Golimumab", "asFound": "Random allocation", "relevance": "HIGH"}, {"id": "M2052", "name": "Tumor Necrosis Factor Inhibitors", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}